Methamphetamine and lentivirus interactions: Reciprocal enhancement of central nervous system disease

Journal of NeuroVirology

Volumn 16, Issue 4, 2010, Pages 269-279

  Huitron Resendiz, Salvador ^a   Henriksen, Steven J ^b   Barr, Margaret C ^b   Testa, Maria P ^b   Crawford, Elena ^a   Parsons, Loren H ^a   Sanchez Alavez, Manuel ^a   Phillips, Tom R ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

AIDS; Drug abuse; FIV; HIV; Neuropathology; Synergism

Indexed keywords

DOPAMINE TRANSPORTER; METHAMPHETAMINE; MONOAMINE; NEUROTRANSMITTER; BIOGENIC AMINE; CENTRAL STIMULANT AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAT; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG ABUSE; DRUG EXPOSURE; EVOKED AUDITORY RESPONSE; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LENTIVIRINAE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ANIMAL; ASTROCYTE; BRAIN; BRAIN DISEASE; DRUG EFFECT; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

ANIMALS; ASTROCYTES; BIOGENIC MONOAMINES; BRAIN; BRAIN DISEASES; CATS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EVOKED POTENTIALS, AUDITORY; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNODEFICIENCY VIRUS, FELINE; IMMUNOHISTOCHEMISTRY; METHAMPHETAMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78149485609     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550284.2010.497807     Document Type: Article

References (75)

1. Abbruzzese G, Rizzo F, Dall'Agata D, Morandi N, Favale E (1990). Generalized dystonia with bilateral striatalcompu-ted-tomographic lucenciesinapatient with human immunodeficiency virus infection. Eur Neurol 30: 271-273.
2. Albers DS, Sonsalla PK (1995). Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275: 1104-1114.
3. Angrist B (1994). Amphetamine psychosis: clinical variation of the syndrome. San Diego: Academic Press.
4. Barr MC, Billaud JN, Selway DR, Huitron-Resendiz S, Osborn KG, Henriksen SJ, Phillips TR (2000a). Effects of multiple acute morphine exposures on feline immunodeficiency virus disease progression. J Infect Dis 182: 725-732.
5. Barr MC, Huitron-Resendiz S, Sanchez-Alavez M, Henriksen SJ, Phillips TR (2003). Escalating morphine exposures followed by withdrawal in feline immunodeficiency virus-infected cats. Drug Alcohol Depend 72: 141-149.
6. Barr MC, Huitron-Resendiz S, Selway DR, Henriksen SJ, Phillips TR (2000b). Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection. J Infect Dis 181: 576-586.
7. Bell JE, Brettle RP, Chiswick A, Simmonds P (1998). HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 121(Pt 11): 2043-2052.
8. Berger JR, Nath A (1997). HIV dementia and the basal ganglia. Intervirology 40: 122-131.
9. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC (1998). Variable progression of HIV-associated dementia. Neurology 50: 1814-1820.
10. Broening HW, Pu C, Vorhees CV (1997). Methamphet-amine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse 27: 153-160.
11. Callahan B, Yuan J, Stover G, Hatzidimitriou G, Ricaurte G (1998). Effects of 2-deoxy-D-glucose on methampheta-mine-induced dopamine and serotonin neurotoxicity. J Neurochem 70: 190-197.
12. Cappon GD, Morford LL, Vorhees CV (1997). Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Brain Res Dev Brain Res 103: 155-162.
13. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF (2003). HIV-1 protein Tat potentiation of methamphe-tamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984: 133-142.
14. Cass WA, Manning MW (1999). Recovery of presynaptic dopaminergic functioning in rats treated with neuro-toxic doses of methamphetamine. J Neurosci 19: 7653-7660.
15. Castello E, Baroni N, Pallestrini E (1998). Neurotological auditory brain stem response findings in human immunodeficiency virus-positive patients without neurologic manifestations. Ann Otol Rhinol Laryngol 107: 1054-1060.
16. Cazzullo CL, Gala C, Ducati A, Landi A, Donati R, Russo R, Rossini M, Nicolosi A (1990). Multimodality evoked potentials in HIV infected subjects: a longitudinal study. Ital J Neurol Sci 11: 481-485.
17. Chang L, Ernst T, Speck O, Grob CS (2005). Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162: 361-369.
18. Christensen LA, Morehouse CR, Powell TW, Alchediak T, Silio M (1998). Antiviral therapy in a child with pedi-atric human immunodeficiency virus (HIV): case study of audiologic findings. J Am Acad Audiol 9: 292-298.
19. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987). Biochemical and histo-logical evidence that methylenedioxymethylampheta- mine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241: 338-345.
20. Corsi KF, Booth RE (2008). HIV sex risk behaviors among heterosexual methamphetamine users: literature review from 2000 to present. Curr Drug Abuse Rev 1: 292-296.
21. Crews L, Patrick C, Achim CL, Everall IP, Masliah E (2009). Molecular pathology of Neuro-AIDS (CNS-HIV). Int J Mol Sci 10: 1045-1063.
22. Ellinwood EH, Jr., Escalante O (1970). Behavior and his-topathological findings during chronic methedrine intoxication. Biol Psychiatry 2: 27-39.
23. Everall I, Luthert P, Lantos P (1993). A review of neuronal damage in human immunodeficiency virus infection: its assessment, possible mechanism and relationship to dementia. J Neuropathol Exp Neurol 52: 561-566.
24. Ferris MJ, Mactutus CF, Booze RM (2008). Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 32: 883-909.
25. Fox HS, Weed MR, Huitron-Resendiz S, Baig J, Horn TF, Dailey PJ, Bischofberger N, Henriksen SJ (2000). Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected monkeys. J Clin Invest 106: 37-45.
26. Gavrilin MA, Mathes LE, Podell M (2002). Methamphet-amine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J NeuroVirol 8: 240-249.
27. Gruol DL, Yu N, Parsons KL, Billaud JN, Elder JH, Phillips TR (1998). Neurotoxic effects of feline immunodeficiency virus, FIV-PPR. J NeuroVirol 4: 415-425.
28. Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, Fleckenstein AE (2009). Metham-phetamine-induced dopaminergic deficits and refractoriness to subsequent treatment. Eur J Pharmacol 607: 68-73.
29. Hausler R, Vibert D, Koralnik IJ, Hirschel B (1991). Neuro-otological manifestations in different stages of HIV infection. Acta Otolaryngol Suppl 481: 515-521.
30. Henriksen SJ, Prospero-Garcia O, Phillips TR, Fox HS, Bloom FE, Elder JH (1995). Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. In: Current topics in microbiology and immunology: HIV and dementia. Oldstone MBA, Vitkovic L (eds). Springer, Berlin, Germany. pp 167-186.
31. Jaffe J (1990). Drug addiction and drug abuse. In: The pharmacological basis of therapeutics, 8th ed. Alfred G Gilman, Alan S Nies, Theodore W Rall, Palmer Tayler (eds). New York: McGraw-Hill, pp 522-573.
32. Kipke MD, O'Connor S, Palmer R, MacKenzie RG (1995). Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection. Arch Pediatr Adolesc Med 149: 513-519.
33. Klein D, Leutenegger CM, Bahula C, Gold P, Hofmann-Lehmann R, Salmons B, Lutz H, Gunzburg WH (2001). Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase- polymerase chain reaction for feline immunodeficiency virus. J Acquir Immune Defic Syndr 26: 8-20.
34. Kogan FJ, Nichols WK, Gibb JW (1976). Influence of meth-amphetamine on nigral and striatal tyrosine hydroxy-lase activity and on striatal dopamine levels. Eur J Pharmacol 36: 363-371.
35. Langford D, Adame A, Grigorian A, Grant I, McCutchan JA, Ellis RJ, Marcotte TD, Masliah E (2003). Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 34: 467-474.
36. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, Wang YJ, Zhou L, Ho WZ (2008). Methamphetamine enhances HIV infection of macrophages. Am J Pathol 172: 1617-1624.
37. Maragos WF, Young KL, Turchan JT, Guseva M, Pauly JR, Nath A, Cass WA (2002). Human immunodeficiency virus-1 Tat protein and methamphetamine interact syn-ergistically to impair striatal dopaminergic function. J Neurochem 83: 955-963.
38. Masliah E, Ge N, Achim CL, Hansen LA, Wiley CA (1992). Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 51: 585-593.
39. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I, Group H (1997). Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol 42: 963-972.
40. Meeker RB, Thiede BA, Hall C, English R, Tompkins M (1997). Cortical cell loss in asymptomatic cats experimentally infected with feline immunodeficiency virus. AIDS Res Hum Retroviruses 13: 1131-1140.
41. Molitor F, Truax SR, Ruiz JD, Sun RK (1998). Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med 168: 93-97.
42. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA (1990). Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci 600: 649-661; discussion 661-1644
43. Moore DJ, Masliah E, Rippeth JD, Gonzalez R, Carey CL, Cherner M, Ellis RJ, Achim CL, Marcotte TD, Heaton RK, Grant I (2006). Cortical and subcortical neurodegeneration is associated with HIV neurocogni-tive impairment. AIDS 20: 879-887.
44. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, Cass W, Turchan JT (2002). Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 31(Suppl 2): S62-S69.
45. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR (2001). Acceleration of HIV dementia with methamphet-amine and cocaine. J NeuroVirol 7: 66-71.
46. Ollo C, Johnson R, Jr., Grafman J (1991). Signs of cognitive change in HIV disease: an event-related brain potential study. Neurology 41: 209-215.
47. Pardo J, Marcos A, Bhathal H, Castro M, Varea de Seijas E (1998). Chorea as a form of presentation of human immunodeficiency virus-associated dementia complex. Neurology 50: 568-569.
48. Phillips TR, Billaud JN, Henriksen SJ (2000). Methamphet-amine and HIV-1: potential interactions and the use of the FIV/cat model. J Psychopharmacol 14: 244-250.
49. Phillips TR, Prospero-Garcia O, Puaoi DL, Lerner DL, Fox HS, Olmsted RA, Bloom FE, Henriksen SJ, Elder JH (1994). Neurological abnormalities associated with feline immunodeficiency virus infection. J Gen Virol 75: 979-987.
50. Phillips TR, Prospero-Garcia O, Wheeler DW, Wagaman PC, Lerner DL, Fox HS, Whalen LR, Bloom FE, Elder JH, Henriksen SJ (1996). Neurologic dysfunctions caused by a molecular clone of feline immunodeficiency virus, FIV-PPR. J NeuroVirol 2: 388-396.
51. Power C, Kong PA, Crawford TO, Wesselingh S, Glass JD, McArthur JC, Trapp BD (1993). Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 34: 339-350.
52. Prospero-Garcia O, Gold LH, Fox HS, Polis I, Koob GF, Bloom FE, Henriksen SJ (1996). Microglia-passaged simian immunodeficiency virus induces neurophysio-logical abnormalities in monkeys. Proc Natl Acad Sci USA 93: 14158-14163.
53. Prospero-Garcia O, Herold N, Phillips T, Elder J, Bloom FE, Henriksen SJ (1994a). Sleep patterns are disturbed in cats infected with feline immunodeficiency virus. Proc Natl Acad Sci USA. 91: 12947-12951.
54. Prospero-Garcia O, Herold N, Waters A, Phillips T, Elder J, Henriksen SJ (1994b). Intraventricular administration of a FIV-envelope protein induces sleep architecture changes in rats. Brain Res 659: 254-258.
55. Prospero-Garcia O, Huitron-Resendiz S, Casalman SC, Sanchez-Alavez M, Diaz-Ruiz O, Navarro L, Lerner DL, Phillips TR, Elder JH, Henriksen SJ (1999). Feline immunodeficiency virus envelope protein (FIVgp120) causes electrophysiological alterations in rats. Brain Res 836: 203-209.
56. Raymond LA, Wallace D, Berman NE, Marcario J, Foresman L, Joag SV, Raghavan R, Narayan O, Cheney PD (1998). Auditory brainstem responses in a Rhesus Macaque model of neuro-AIDS. J NeuroVirol 4: 512-520.
57. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991). Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol (Berl) 82: 39-44.
58. Reyes-Contreras L, Silva-Rojas A, Ysunza-Rivera A, Jimenez-Ruiz G, Berruecos-Villalobos P, Romo-Gutierrez G (2002). Brainstem auditory evoked response in HIV-infected patients with and without AIDS. Arch Med Res 33: 25-28.
59. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY (1982). Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235: 93-103.
60. Ricaurte GA, McCann UD (1992). Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci 648: 371-382.
61. Rotheram-Borus MJ, Cajetan Luna G, Marotta T, Kelly H (1994). Going nowhere fast: Methamphetamine use and HIV infection. NIDA Res Monogr 143: 155-182.
62. Sahakian BJ, Elliott R, Low N, Mehta M, Clark RT, Pozniak AL (1995). Neuropsychological deficits in tests of executive function in asymptomatic and symptomatic HIV-1 seropositive men. Psychol Med 25: 1233-1246.
63. Sardar AM, Czudek C, Reynolds GP (1996). Dopamine deficits in the brain: the neurochemical basis of parkin-sonian symptoms in AIDS. Neuroreport 7: 910-912.
64. Semple SJ, Strathdee SA, Zians J, Patterson TL (2009). Sexual risk behavior associated with co-administration of methamphetamine and other drugs in a sample of HIV-positive men who have sex with men. Am J Addict 18: 65-72.
65. Smith T, Jakobsen J, Gaub J, Helweg-Larsen S, Trojaborg W (1988). Clinical and electrophysiological studies of human immunodeficiency virus-seropositive men without AIDS. Ann Neurol 23: 295-297.
66. Taffe MA, Davis SA, Yuan J, Schroeder R, Hatzidimitriou G, Parsons LH, Ricaurte GA, Gold LH (2002). Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neurop-sychopharmacology 27: 993-1005.
67. Theodore S, Stolberg S, Cass WA, Maragos WF (2006). Human immunodeficiency virus-1 protein tat and meth-amphetamine interactions. Ann N Y Acad Sci 1074: 178-190.
68. Theodore S, Cass WA, Nath A, Maragos WF (2007). Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr HIV Res 5: 301-313.
69. Vigliano P, Boffi P, Bonassi E, Gandione M, Marotta C, Raino E, Russo R, Rigardetto R (2000). Neuro-physiologic exploration: a reliable tool in HIV-1 encephalopathy diagnosis in children. Panminerva Med 42: 267-272.
70. Vigliano P, Russo R, Arfelli P, Boffi P, Bonassi E, Gandione M, Raino E, Tovo PA, Taglianti MV, Rigardetto R (1997). Diagnostic value of multimodal evoked potentials in HIV-1 infected children. Neuro-physiol Clin 27: 283-292.
71. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J (1980). Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphet-amine. Brain Res 181: 151-160.
72. Wiley CA, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R (1991). Neocortical damage during HIV infection. Ann Neurol 29: 651-657.
73. Wolfson T, Velin R, Marcotte TD, Hesselink JR, Jernigan TL, Chandler J, Wallace M, Abramson I, THE HNRC GROUP (1995). The HNRC 500\neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1: 231-251.
74. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS (1989). Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486: 73-78.
75. Yu N, Billaud JN, Phillips TR (1998). Effects of feline immunodeficiency virus on astrocyte glutamate uptake: implications for lentivirus-induced central nervous system diseases. Proc Natl Acad Sci USA 95: 2624-2629.